The rapid advancement of Artificial Intelligence has moved us from simple chatbots to autonomous agents. These agents do not just answer questions; they plan, use tools, and execute tasks with minimal ...

COBOL is in the headlines again, and this time it is because of artificial intelligence (AI) – sparking conversations with tools emerging that claim t.

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help accelerate drug discovery through artificial intelligence. December 8, 2025 Recursion Pharma's ...

Abraham Rubio has wanted to be a software engineer since childhood. On the gaming platform Minecraft, he loved tinkering with “mods,” or alterations to video games created by fans that change elements ...

ABSTRACT: The growing demand for energy-efficient Wireless Sensor Networks (WSNs) in applications such as IoT, environmental monitoring, and smart cities has sparked exhaustive research into practical ...

Abstract: This study investigates the influence of personality traits on computer programming performance among computer science students. Programming proficiency is crucial for developing analytical ...

Mikeie Reiland is a staff writer for Education at Forbes Advisor. Before coming to Forbes Advisor, he wrote magazine journalism for publications like the Oxford American, Bitter Southerner, and Gravy.

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...